ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...
The expert in complement therapeutics development, Creative Biolabs, keys the importance of complement function and activity tests in complement defect screening and drug development. The complement ...
CAMBRIDGE, Mass.--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, today announced initial positive results from its ongoing Phase 1/2 clinical trial with ALN-CC5, an ...
CLL primary cells and the CLL cell line HG3 were cultured in RPMI-1640 containing 10% fetal bovine serum, 50 U/ml penicillin, 50 mg/ml streptomycin and 2 mM L-glutamine (complete medium; Invitrogen ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback